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Mitochondrial respiratory chain disorders are char-
acterized by loss of electron transport chain (ETC)
activity. Although the causes of many such diseases
are known, there is a lack of effective therapies.
To identify genes that confer resistance to severe
ETC dysfunction when inactivated, we performed a
genome-wide genetic screen in haploid human cells
with the mitochondrial complex III inhibitor antimy-
cin. This screen revealed that loss of ATPIF1 strongly
protects against antimycin-induced ETC dysfunction
and cell death by allowing for the maintenance of
mitochondrial membrane potential. ATPIF1 loss pro-
tects against other forms of ETC dysfunction and is
even essential for the viability of human r cells lack-
ing mitochondrial DNA, a system commonly used
for studying ETC dysfunction. Importantly, inhibition
of ATPIF1 ameliorates complex III blockade in pri-
mary hepatocytes, a cell type afflicted in severemito-
chondrial disease. Altogether, these results suggest
that inhibition of ATPIF1 can ameliorate severe ETC
dysfunction in mitochondrial pathology.INTRODUCTION
Defects in the activity of the electron transport chain (ETC) are
the causative pathology in a diverse family of genetic diseases
known as mitochondrial respiratory chain disorders. Patients
with these diseases can often present with abnormalities in mul-
tiple organ systems (Pfeffer et al., 2012; DiMauro and Schon,
2003; Spinazzola et al., 2006). Although somemitochondrial res-piratory chain disorders cause relatively mild abnormalities, such
as exercise intolerance, there are severe forms of respiratory
chain disorders that can lead to life-threatening loss of tissue pa-
renchyma and organ failure (Morris, 1999; Lee and Sokol, 2007;
DiMauro and Schon, 2003; Spinazzola et al., 2006). Yet, despite
an extensive characterization of the mechanisms underlying
these diseases, there is a paucity of effective therapies to
ameliorate severe respiratory chain dysfunction. Indeed, most
efforts to date, such as dietary supplementation with small mol-
ecules and vitamins that can increase ETC activity or decrease
reactive oxygen species, have not demonstrated any clear effi-
cacy across clinical trials, thus underscoring the need for novel
therapeutic strategies (Pfeffer et al., 2012; Schon et al., 2010).
Genetic and chemical screens in mammalian cells have previ-
ously identified modulators of mitochondrial dynamics (Lefebvre
et al., 2013; Kitami et al., 2012; Gohil et al., 2010; Yoon et al.,
2010), but genetic screens have not identified gene products in
mammalian cells that, when inactivated, increase survival under
ETC dysfunction. Beginning with a positive selection screen in
human cells using the mitochondrial complex III inhibitor antimy-
cin, we find that loss of ATPIF1 is protective against complex III
blockade, as well as a multitude of other insults to the ETC, lead-
ing us to propose inhibition of ATPIF1 as a strategy for amelio-
rating severe mitochondrial respiratory chain disorders.RESULTS AND DISCUSSION
To identify genes whose productsmodulate sensitivity to ETC in-
hibition, we performed a genome-wide, insertional mutagenesis
screen in the near-haploid KBM7 human cell line with antimycin,
a complex III inhibitor of the ETC. This technology has been used
successfully in the past to identify numerous proteins that are
essential for the cytotoxicity of microbial factors (Carette et al.,
2011b; Guimaraes et al., 2011), as well as transporters for toxicCell Reports 7, 27–34, April 10, 2014 ª2014 The Authors 27
Figure 1. Haploid Genetic Screen Identifies Loss of ATPIF1 as Protective against Complex III Inhibition
(A) Mutagenized KBM7 cells were treated with antimycin and resistant cells were pooled. Gene-trap insertions were identified by massively parallel sequencing
and mapped to the human genome. The y axis represents the statistical significance of a given gene, and the x axis represents the collection of genes with
insertions. The red line indicates the cutoff of statistical significance chosen to determine whether a gene scored as a hit in the screen. For ATPIF1, WT1, and
TP53, the number of unique insertions per gene is given in parentheses.
(B) Map of unique insertions in ATPIF1 in the resistant cell population. The arrow denotes 50-30 directionality, boxes represent exons, and black bars indicate
insertions.
(C) Immunoblots for the indicated proteins in WT and ATPIF1_KO KBM7 cells.
(D) Micrographs (left) and viability (right) of WT and ATPIF1_KO KBM7 cells treated with antimycin for 4 days. Error bars are ± SEM (n = 3). Scale bars, 20 mm.
(E) Immunoblots for the indicated proteins inWT, ATPIF1_KO, and ATPIF1_KO KBM7 cells with restored ATPIF1 expression (left) and viability of cells treated with
antimycin (135 mM) for 2 days (right). Error bars are ± SEM (n = 3). ***p < 0.001.
(F) Cellular ATP (left) and DJm (right) in WT and ATPIF1_KO KBM7 cells treated with antimycin (135 mM) and oligomycin (1 mM). Error bars are ± SEM (n = 3).
(G) Viability of WT and ATPIF1_KO KBM7 cells treated with antimycin (135 mM) and oligomycin (1 mM) for 2 days. Error bars are ± SEM (n = 3). ***p < 0.001.
See also Figures S1–S3 and Table S1.small molecules (Birsoy et al., 2013). In brief, we generated a
library of mutagenized haploid KBM7 cells harboring approxi-
mately 70 million insertions that encompass more than 95% of
all genes expressed in KBM7 cells (Carette et al., 2011a). Muta-
genized cells were then treated with antimycin for 3 weeks and
the surviving cells were expanded and pooled. Insertions in the
surviving population were mapped to the human genome using
massively parallel sequencing. To identify genomic loci enriched
for gene-trap insertions, we performed a proximity index analysis
and identified several candidate genes: ATPIF1 (p = 3.04 328 Cell Reports 7, 27–34, April 10, 2014 ª2014 The Authors1043),WT1 (p = 1.783 1040), and TP53 (p = 6.93 3 108; Fig-
ure 1A). Because both WT1 and TP53 are tumor suppressors
(Sherr, 2004) and therefore would be less attractive therapeutic
targets, we focused our attention on ATPIF1. ATPIF1 is a highly
conserved mitochondrial protein that inhibits the ATPase activity
of the F1-F0 ATP synthase and has been found to affect a variety
of metabolic parameters, such as aerobic glycolysis (Sa´nchez-
Cenizo et al., 2010), ATP synthase dimerization (Garcı´a et al.,
2006), and mitochondrial cristae density (Campanella et al.,
2008, 2009).
To investigate the role of ATPIF1 loss in protecting cells against
complex III blockade, we isolated a KBM7 clone harboring a
gene-trap insertion of ATPIF1 (ATPIF1_KO) and confirmed that
it did not express detectable amounts of ATPIF1 protein (Figures
1Band 1C). Consistent with the results of our screen, ATPIF1_KO
cells were substantially more resistant to antimycin-induced cell
death than their wild-type (WT) counterparts (Figure 1D). Addi-
tionally, re-expression of ATPIF1 in ATPIF1_KO cells almost
completely restored their sensitivity to antimycin (Figure 1E). As
an independent confirmation of our findings, WT KBM7 cells
expressing small hairpin RNAs (shRNAs) targeting ATPIF1 also
exhibited increased resistance to antimycin (Figure S1).
To probe the mechanism by which ATPIF1 loss can confer
resistance to complex III inhibition, we examined the effects
of antimycin on the metabolism and mitochondrial function of
WT and ATPIF1_KO KBM7 cells. Upon inhibition of the ETC,
the mitochondrial membrane potential (DJm) decreases and
the F1-F0 ATP synthase reverses, consuming ATP to pump pro-
tons into the intermembrane space (Campanella et al., 2008,
2009; Lefebvre et al., 2013; Lu et al., 2001). Normally an inactive
tetramer, ATPIF1 dissociates into active dimers upon a large
decrease in DJm and subsequently inhibits reversal of the
F1-F0 ATP synthase, an adaptive mechanism to prevent ATP
consumption during periods of nutrient and oxygen deprivation
(Cabezo´n et al., 2001; Fujikawa et al., 2012; Lu et al., 2001; Cam-
panella et al., 2008, 2009). In short-term experiments, decreased
ATPIF1 activity during ETC dysfunction allows for maintenance
of DJm at the expense of ATP via reversal of the F1-F0 ATP syn-
thase, but it is unclear whether maintenance of DJm or conser-
vation of ATP is the most important process for survival under
ETC dysfunction (Campanella et al., 2008, 2009; Lefebvre
et al., 2013). Consistent with the F1-F0 ATP synthase operating
in reverse, we observed that ATPIF1_KO cells had decreased
ATP but increased DJm upon antimycin treatment as compared
with WT KBM7 cells (Figure 1F). Metabolite profiling of
ATPIF1_KO cells under antimycin treatment also revealed a
greater depletion of glycolytic intermediates, in agreement with
the increased ATP demand under conditions of ETC inhibition
(Figure S2; Table S1). Importantly, the differences seen in ATP,
DJm, and overall survival under antimycin could be eliminated
by cotreatment with oligomycin, a potent inhibitor of the F1-F0
ATP synthase (Figures 1F and 1G). It is unlikely that the effects
of oligomycin on antimycin-treated cells were a result of additive
toxicity, because oligomycin itself had no effect on the viability of
either WT KBM7 or ATPIF1_KO cells (Figure 1G). Of note, the
addition of oligomycin to antimycin-treated ATPIF1_KO cells
decreased DJm and increased ATP levels, but led to decreased
survival, suggesting that maintenance of DJm is more important
than preservation of ATP for ameliorating complex III blockade in
KBM7 cells. To rule out any effects of ATPIF1 loss on general
mitochondrial metabolism and cellular physiology, we also
examined the mitochondrial mass, mtDNA copy number, mito-
chondrial ultrastructure, and resting DJm, ATP, viability, and ox-
ygen consumption of WT and ATPIF1_KO KBM7 cells, but found
no significant differences (Campanella et al., 2008; Figure S3).
Collectively, these data demonstrate that ATPIF1 loss confers
resistance to complex III blockade through maintenance of
DJm via reversal of the F1-F0 ATP synthase.We next sought to determine whether the effects of ATPIF1
loss on KBM7 cells were generalizable to other cell lines and
additional forms of ETC dysfunction. Consistent with the results
in KBM7 cells, SH-SY5Y and HeLa cells expressing an shRNA
targeting ATPIF1 were more resistant to antimycin than cells ex-
pressing a control hairpin (Figure 2A). In addition, we found that
overexpression of ATPIF1 in Malme-3M, a cell line with low
endogenous levels of ATPIF1, increased their sensitivity to anti-
mycin (Figure 2B). To investigate whether the protective effect of
ATPIF1 loss was limited to only complex III inhibition, we tested a
variety of pharmacological and genetic models of ETC dysfunc-
tion. ATPIF1_KO KBM7 cells were substantially more resistant to
both piericidin, an inhibitor of complex I (Darrouzet et al., 1998),
and tigecycline, an inhibitor of mitochondrial translation (Skrtic
et al., 2011), when compared with their WT counterparts (Fig-
ure 2C). Taken together, these data demonstrate that the levels
of ATPIF1 can modulate sensitivity to different forms of ETC
dysfunction in various human cell lines.
The observation that ATPIF1_KO KBM7 cells were more
resistant to inhibition of complex I, complex III, andmitochondrial
protein synthesis raised the possibility that ATPIF1 loss could
ameliorate the effects of dysfunction in multiple components of
the ETC. To test this genetically, we examined r cells, which
are devoid of any mtDNA and consequently have defects in
complexes I, III, and IV, resulting in undetectable ETC activity
(Jazayeri et al., 2003). To our surprise, we found that HeLar cells
intrinsically possess lower mRNA and protein levels of ATPIF1
compared with their WT counterparts (Figure 2D). Previous
work has shown that r cells maintain DJm by using the electro-
genic exchangeofATPandADP, coupled toATPhydrolysis byan
F1-F0 ATP synthase that is defective in pumping protons, and
that this activity is important for cellular health (Buchet and God-
inot, 1998; Appleby et al., 1999). We therefore hypothesized that
there could be a strong selective pressure to decrease ATPIF1
levels under severe ETC dysfunction in order to facilitate reversal
of the F1-F0 ATP synthase. A reduction of ATPIF1 in 143b r cells
was observed recently, although the functional significance of
this reduction on cell viability was not investigated (Lefebvre
et al., 2013). To address this, we overexpressed WT ATPIF1 or
a mutant ATPIF1 harboring an E55A substitution that renders
the protein unable to interact with the F1-F0 ATP synthase (Ichi-
kawa et al., 2001). Overexpression of WT ATPIF1, but not E55A
ATPIF1, strongly impaired proliferation in HeLa r cells, but not
in HeLa WT cells (Figure 2E). The differences observed between
WT and E55A ATPIF1 were not simply a result of E55A ATPIF1
protein instability, because both variants of ATPIF1 were overex-
pressed to a similar degree, as seen in the immunoblots of HeLa
WT cells (Figure 2E). Intriguingly, at the time of collection, we
found that the surviving HeLa r cells infectedwith virus express-
ingWT ATPIF1 had lower amounts of ATPIF1 than those infected
with virus expressing E55A ATPIF1, which is consistent with a
selection against ATPIF1 activity on the F1-F0 ATP synthase in
the r state (Figure 2E). Collectively, these data demonstrate
that reduced ATPIF1 activity is essential for the viability of human
r cells lacking a mitochondrial genome.
Failure to maintain proper amounts of the mitochondrial
genome is a distinctive feature of a class of severe respiratory
chain disorders known as mtDNA depletion syndromes (LeeCell Reports 7, 27–34, April 10, 2014 ª2014 The Authors 29
Figure 2. Loss of ATPIF1 Is Beneficial in Both Pharmacological and Genetic Models of ETC Dysfunction
(A) Left: immunoblots for the indicated proteins in SH-SY5Y cells expressing a control shRNA against Luciferase (shLuc) or an shRNA against ATPIF1
(shATPIF1_3). Middle and right: viability of SH-SY5Y (middle) and HeLa (right) cells treated with antimycin for 4 days. Error bars are ± SEM (n = 3).
(B) Left: immunoblots for the indicated proteins in Malme-3M cells overexpressing control RAP2A or ATPIF1. Right: viability of Malme-3M cells treated with
antimycin for 4 days. Error bars are ± SEM (n = 3).
(C) Viability of WT and ATPIF1_KO KBM7 cells treated with piericidin (top) or tigecycline (bottom) for 4 days. Error bars are ± SEM (n = 3).
(D) Relative ATPIF1 mRNA levels (top) and immunoblots for the indicated proteins (bottom) in HeLa WT and r cells. Error bars are ± SEM (n = 3). **p < 0.01.
(E) Immunoblots (left) and relative proliferation (right) of HeLaWT and r cells transducedwith control vector, ATPIF1 (WT), or ATPIF1 (E55A) constructs. Error bars
are ± SEM (n = 3).and Sokol, 2007). Because of our interest in ATPIF1 inhibition as
a potential strategy for ameliorating severe ETC dysfunction, we
asked whether loss of ATPIF1 alone was sufficient to improve
cell viability during progressive mtDNA depletion. For this pur-
pose, we cultured WT and ATPIF1_KO KBM7 cells with 20,30-di-
deoxyinosine (ddI), an inhibitor of mtDNA replication (Lewis et al.,
2003; Walker et al., 2002), for approximately 51 days and moni-
tored cellular behavior at defined time points (Figure 3A; see
Experimental Procedures for the exact time points at which phe-
notypes were assayed). ddI led to an immediate decrease in
mtDNA copy number in the initial days of treatment concomi-
tantly with a decrease in cell proliferation that was roughly equiv-
alent betweenWT and ATPIF1_KOKBM7 cells (Figure 3B). It was
previously observed that this amount of mtDNA depletion still
allows for residual ETC function (Jazayeri et al., 2003), so it is
unlikely that ATPIF1 was maximally activated in the WT KBM7
cells at this point. mtDNA was progressively depleted with
each successive week of ddI treatment, and by day 25, both
WT and ATPIF1_KO KBM7 cells had trace amounts of mtDNA
(Figure 3C). Although both WT and ATPIF1_KO KBM7 cells
proliferated more slowly than their untreated counterparts,
ATPIF1_KO cells demonstrated a significantly faster rate of pro-30 Cell Reports 7, 27–34, April 10, 2014 ª2014 The Authorsliferation than WT KBM7 cells, consistent with loss of ATPIF1
improving cell viability under conditions of severe ETC dysfunc-
tion (Figure 3C). Taken together, these data demonstrate that
loss of ATPIF1 is sufficient to improve cell viability during pro-
gressive mtDNA depletion.
Given that low ATPIF1 levels were necessary for viability in
HeLa r cells, we hypothesized that WT r KBM7 cells would ex-
press low amounts of ATPIF1 aswell. In accordancewith this, we
observed a gradual decrease in ATPIF1 over 50 days of ddI treat-
ment, with WT KBM7 cells exhibiting substantially reduced
amounts of ATPIF1 and undetectable quantities of mtDNA (i.e.,
r state) at the end of the time course (Figures 3B–3D). Further-
more, WT r KBM7 cells with reduced ATPIF1 expression
proliferated to a similar extent as ATPIF1_KO r KBM7cells, sug-
gesting that complete loss of ATPIF1 activity had no additional
benefit for cell proliferation in the terminal r state (Figure 3D).
Because severe forms of mitochondrial respiratory chain dis-
orders can lead to cell death and loss of tissue parenchyma in or-
gans such as the liver (Morris, 1999; Lee and Sokol, 2007), we
transitioned to a more physiological context and asked whether
loss of ATPIF1 in hepatocytes could ameliorate ETC dysfunction
and improve cell viability. WT andATPIF1/micewere obtained
Figure 3. Loss of ATPIF1 Improves
Cell Viability during Progressive mtDNA
Depletion
(A) Schematic depicting the experimental para-
digm for long-term treatment of WT and
ATPIF1_KO KBM7 cells with ddI. Early (days
0–10), middle (days 10–40), and late (days 40+)
periods of ddI treatment are indicated and
demarcated by dotted lines. During each period,
mtDNA copy number, cell proliferation over
4 days, and ATPIF1 expression were analyzed.
(B–D) mtDNA copy number (left), cell proliferation
(middle), and immunoblots for the indicated pro-
teins (right) of WT and ATPIF1_KO KBM7 cells
treated with ddI during the early (B), middle (C),
and late (D) periods. Error bars are ± SEM (n = 3).
***p < 0.001.from the International Knockout Mouse Consortium (Brown and
Moore, 2012; Figures S4A and S4B), and primary hepatocytes
isolated from ATPIF1/ mice had undetectable amounts of
ATPIF1 (Figure 4A). Consistent with the results obtained in cell
lines, antimycin treatment led to a greater decrease in cellular
ATP (Figure 4B) and a greater increase in DJm (Figure 4C) in
ATPIF1/ hepatocytes than in WT hepatocytes, indicating that
there was greater reversal of the F1-F0 ATP synthase in
ATPIF1/ hepatocytes. Importantly, ATPIF1/ hepatocytes
had increased cell viability relative to WT hepatocytes following
treatment with antimycin (Figure 4D). This demonstrates that
the beneficial effects of ATPIF1 loss under severe ETC dysfunc-
tion are not limited to rapidly proliferating cancer cell lines and
can also occur in postmitotic, differentiated cells that better
recapitulate the metabolism of tissues affected in severe mito-
chondrial respiratory chain disorders (Vander Heiden et al.,
2009). The smaller effects of ATPIF1 loss on hepatocyte viability
during antimycin treatment, as compared with KBM7 cells,Cell Reports 7, 27are partially due to the frailty of pri-
mary mouse hepatocytes when cultured
ex vivo (Edwards et al., 2013; Klaunig
et al., 1981). Taken together, these data
demonstrate that ATPIF1 loss in primary
hepatocytes can ameliorate the effects
of complex III blockade.
Our results suggest that ATPIF1 inhibi-
tion can be a strategy for ameliorating
severe ETC dysfunction in mitochondrial
respiratory chain disorders. Impaired
ETC function in the presence of normal
ATPIF1 activity leads to a persistent loss
of DJm, which hinders mitochondrial
import of proteins (Neupert, 1997) and
eventually promotes apoptosis (Gottlieb
et al., 2003). However, upon ATPIF1 inhi-
bition, increased reversal of the F1-F0
ATP synthase can bolster DJm and
improve mitochondrial and cellular health
(Figure 4E), although it remains to be seen
whether ATPIF1 loss is beneficial to allcell types in vivo since the ratio of ATPIF1 to F1-F0 ATP synthase
expression, the amount of glycolysis, and the consumption of
ATP can vary substantially among different tissues. Regardless,
because several mitochondrial respiratory chain disorders, such
as Alpers-Huttenlocher syndrome and Pearson’s syndrome,
lead to progressive liver failure (Lee and Sokol, 2007), our find-
ings in primary hepatocytes at least suggest that hepatic delivery
of RNAi constructs targeting ATPIF1 either via adeno-associated
virus or lipid nanoparticles, both of which have shown clinical ef-
ficacy in gene therapy of the liver, may have therapeutic value
(Nathwani et al., 2011; Fitzgerald et al., 2014). Notably,
ATPIF1/mice appear phenotypically normal and their hepato-
cytes exhibit no significant alterations in ATP synthase activity or
mitochondrial structure (Nakamura et al., 2013). In agreement
with these findings, we did not observe any significant differ-
ences in the mitochondrial mass of WT and ATPIF1/ primary
hepatocytes (Figure S4C). Altogether, these data suggest that
ATPIF1 inhibition is relatively well tolerated.–34, April 10, 2014 ª2014 The Authors 31
Figure 4. Inhibition of ATPIF1 Ameliorates the Effects of Complex III
Blockade in Primary Hepatocytes
(A) Immunoblots for the indicated proteins of primary hepatocytes derived
from WT and ATPIF1/ mice.
(B) Cellular ATP of WT and ATPIF1/ primary hepatocytes treated with anti-
mycin (0.625 mM) for 1.5 hr. Error bars are ± SEM (n = 3). ***p < 0.001.
(C) DJm of WT and ATPIF1
/ primary hepatocytes treated with antimycin
(10 mM) for 1.5 hr. Error bars are ± SEM (n = 3). **p < 0.01.
(D) Viability of WT and ATPIF1/ primary hepatocytes treated with antimycin
(1.25 mM) for 2 days. Error bars are ± SEM (n = 3). **p < 0.01.
(E) Schematic diagramming the behavior of cells with ETC dysfunction under
conditions in which ATPIF1 is active or inhibited. Inhibition of ATPIF1 is de-
picted by absence of the protein, but represents any strategy to block ATPIF1
activity on the F1-F0 ATP synthase.
See also Figure S4.In conclusion, we have used a positive selection screening
method in human cells to identify loss of ATPIF1 as protec-
tive against complex III blockade. We have further shown
that ATPIF1 inhibition protects different cell types against
numerous insults to the ETC. In particular, our work demon-
strates that loss of ATPIF1 activity is essential for the viability
of human r cells, a widely used system to study mitochondrial
dysfunction, and that inhibition of ATPIF1 can ameliorate
the effects of complex III blockade in primary hepatocytes,
a cell type that is often affected in severe respiratory chain dis-
orders. Given the lack of therapies for severe mitochondrial
respiratory chain disorders, we thus believe that inhibition
of ATPIF1 is a promising approach that warrants further
investigation.32 Cell Reports 7, 27–34, April 10, 2014 ª2014 The AuthorsEXPERIMENTAL PROCEDURES
Fluorescence-Activated Cell Sorting Assays
For fluorescence-activated cell sorting (FACS) assays, measurements of DJm
were obtained by incubating 100,000 cells with tetramethylrhodamine methyl
ester (TMRM, 25 nM) and the indicated amounts of drugs for the indicated
amounts of time before collection. For measurements of mitochondrial
mass, 100,000 cells were incubated with MitoTracker Green FM (50 nM) for
1 hr. For primary hepatocytes, cells were assayed in suspension immediately
after they were harvested from the liver, and incubated with verapamil (20 mM)
to facilitate retention of TMRM and MitoTracker Green FM signals. Afterward,
cells were collected by centrifugation, washed once with PBS, and resus-
pended in PBS with 7-AAD (2 mg/ml) for analysis. KBM7 cells and primary
hepatocytes were centrifuged at 2,000 rpm for 5 min and 500 rpm for 5 min
at 4C, respectively.
Cell Viability Assays
For KBM7 cells, 100,000 cells were seeded and treated with the indicated
drugs for the indicated amounts of time. They were then analyzed by 7-AAD
staining and FACS (BD Pharmingen) according to the manufacturer’s instruc-
tions unless indicated otherwise. For HeLa, SH-SY5Y, and Malme-3M cells,
500–2,000 cells were seeded per well of white, clear-bottom, 96-well plates
(Greiner Bio-One), treated with drugs, and then analyzed using CellTiter-Glo
(Promega) according to the manufacturer’s instructions. For primary hepato-
cytes, 100,000 cells were seeded per well of a 24-well TPP plate (Light
Labs), treated with antimycin, and then analyzed using CellTiter-Glo.
Cell Proliferation Assays
For KBM7 cells, cell proliferation was assessed with a Beckman Z2 Coulter
Counter using a size range of 8–30 mm. For all other cell lines, cell proliferation
was assessed using CellTiter-Glo according to themanufacturer’s instructions
and by normalizing all readings to initial values measured at the start of the
experiment.
Long-Term Exposure to ddI
mtDNA copy number analysis was performed on cells treated with ddI for 8,
26, and 41 days. Rates of proliferation were measured for cells treated with
ddI for 5, 31, and 51 days. Immunoblot analysis was done on cells treated
with ddI for 5, 11, and 50 days.
Statistical Analysis
All data are expressed as mean ± SEM. Significance was determined with
a two-tailed unpaired Student’s t test. Differences with a p value less than
0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
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